Abstract Library

#4355 Emergence of DNA damage repair clonal haematopoiesis after peptide receptor radionuclide therapy for neuroendocrine tumours

Introduction: In neuroendocrine tumours (NETs), PRRT (Peptide Receptor Radionuclide Therapy), has shown efficacy but with significant hematologic toxicity. Clonal haematopoiesis (CHIP) is considered a risk factor for therapy-related myeloid neoplasms (t-MN).

Conference:

Presenting Author: Hadoux J

Authors: Loyaux R, Hadoux J, Oziel-Taieb S, Durand A, Bouhier Leporrier K,

Keywords: PRRT, clonal haematopoiesis, DNA Damage Repair, therapy-related myeloid neoplasm, Neuroendocrine tumour,

#4251 Upfront Oxaliplatin–Fluoropyrimidine chemotherapy and Somatostatin Analogues (SSA) in advanced well-differentiated G2/G3 gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs)

Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are frequently diagnosed at advanced stage. For well-differentiated somatostatin receptor-positive (SSTR +) NETs, somatostatin analogues (SSAs) are the preferred first-line therapy. However, in patients (pts) with G2/G3 and a high tumor burden, SSA alone might not be enough.

Conference:

Presenting Author:

Authors: Maratta M, Sparagna I, d'Agostino F, Occhipinti D, Raia S,

Keywords: gastroenteropancreatic NET, neuroendocrine tumor, chemotherapy, conversion surgery, neoadjuvant treatment,

#4193 Pivotal role of the multidisciplinary tumor board on the management of neuroendocrine neoplasms – Impact of MTB decisions in an ENETS Center of Excellence

Introduction: Multidisciplinary Tumor Board (MTB) meetings are a valuable tool to improve the management of solid tumors. Yet, few evidences regarding the real-world impact of Neuroendocrine Neoplasm (NEN)-dedicated MTBs are available.

Conference:

Presenting Author:

Authors: Maratta M, Vitale A, Occhipinti D, Raia S, Menotti S,

Keywords: multidisciplinary tumor board, neuroendocrine cancer, disease management, patient care,

#4095 CAPTEM and PRRT to improve overall response for pancreatic NETs (pNETs) – The CORONET trial

Introduction: Patients with advanced pNETs have limited treatment options. The NETTER-2 and OCLURANDOM trials have established peptide receptor radionuclide therapy (PRRT) as a standard treatment in pNETs; CAPTEM chemotherapy is an active regimen in NENs. The CONTROL NETs trial has shown promising response rate and progression-free survival with PRRT+CAPTEM, warranting further investigation.

Conference:

Presenting Author:

Authors: Chan D, Doherty M, Singh S, Michael M, Kong G,

Keywords: PRRT, CAPTEM, Randomized Trial, Phase III,

#3997 FOXA2-initiated transcriptional activation of INHBA induced by methylmalonic acid promotes pancreatic neuroendocrine neoplasm progression

Introduction: More than 60% of pancreatic neuroendocrine neoplasms (PanNENs) represent metastases when diagnosed. Metabolic alterations have been recognized as one of the hallmarks of tumor metastasis. However, little is known about the molecular mechanism of metabolic changes regulating PanNEN progression.

Conference:

Presenting Author:

Authors: Hu C,

Keywords: metabolic alteration, tumor progression, pancreatic neuroendocrine neoplasm, FOXA2, INHBA, epithelial-mesenchymal transition,